Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for ImmunityBio (IBRX) over the last 11 years, with Q1 2025 value amounting to $5.4 million.

  • ImmunityBio's Change in Acquisitions & Divestments fell 5891.25% to $5.4 million in Q1 2025 from the same period last year, while for Sep 2025 it was $23.4 million, marking a year-over-year decrease of 7825.76%. This contributed to the annual value of $115.6 million for FY2024, which is 104441.58% up from last year.
  • Latest data reveals that ImmunityBio reported Change in Acquisitions & Divestments of $5.4 million as of Q1 2025, which was down 5891.25% from $18.0 million recorded in Q4 2024.
  • In the past 5 years, ImmunityBio's Change in Acquisitions & Divestments ranged from a high of $99.1 million in Q2 2022 and a low of $102000.0 during Q1 2023
  • For the 5-year period, ImmunityBio's Change in Acquisitions & Divestments averaged around $22.5 million, with its median value being $13.7 million (2022).
  • As far as peak fluctuations go, ImmunityBio's Change in Acquisitions & Divestments plummeted by 9928.9% in 2023, and later soared by 1266568.63% in 2024.
  • ImmunityBio's Change in Acquisitions & Divestments (Quarter) stood at $11.4 million in 2021, then grew by 29.34% to $14.8 million in 2022, then crashed by 32.24% to $10.0 million in 2023, then skyrocketed by 80.38% to $18.0 million in 2024, then crashed by 70.33% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q1 2025, $18.0 million for Q4 2024, and $49.5 million during Q3 2024.